Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02033928 · ClinicalTrials.gov registry record
Comprehensive Frailty Assessment
A clinical trial of Hematologic Neoplasms and Myeloma Multiple, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- 111
- Enrollment target
- 1
- Study location
NCT02033928 is a study of Hematologic Neoplasms and Myeloma Multiple that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 111 participants, below the 1,021-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02033928, a study of Hematologic Neoplasms and Myeloma Multiple, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 111 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to describe a patients' fitness before and after treatment (whether that treatment be chemotherapy or a transplant). Fitness is a way of measuring a patient's current quality of health. With surveys, questionnaires and blood tests, we hope to create a tool that will give a good picture of patients' ability to tolerate treatment. In the future, we hope to devise the best treatment for a patient based on their "fitness".
Conditions Studied
Study Locations (1)
Ohio
- The Ohio State University Hospital East - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2014-04 |
| Est. Completion | 2017-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02033928
The ClinicalTrials.gov registry entry for NCT02033928 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,021-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (89% lower). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hematologic Neoplasms appearing as the primary indexed condition, and to 0 interventions.
NCT02033928 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02033928 about?
NCT02033928 is a clinical study titled "Comprehensive Frailty Assessment". The purpose of this research study is to describe a patients' fitness before and after treatment (whether that treatment be chemotherapy or a transplant). Fitness is a way of measuring a patient's current quality of health. With surveys, questionnaires and blood tests, we hope to create a tool that ...
What is the current status of trial NCT02033928?
This trial is currently completed. The enrollment target is 111 participants. The study started on 2014-04. Estimated completion is 2017-08.
What conditions does trial NCT02033928 study?
This clinical trial studies the following conditions: Hematologic Neoplasms, Myeloma Multiple, Paraproteinemias.
Who is sponsoring clinical trial NCT02033928?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02033928 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
RECRUITING
-
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
RECRUITING · NA
-
UWCCC Molecular Tumor Board Registry
RECRUITING
-
Cognitive Training Intervention and Attitudes Towards Genetics
RECRUITING · NA
-
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.